Fecal Viral Load and Norovirus-associated Gastroenteritis

We report the median cDNA viral load of norovirus genogroup II is >100-fold higher than that of genogroup I in the fecal specimens of patients with norovirus-associated gastroenteritis. We speculate that increased cDNA viral load accounts for the higher transmissibility of genogroup II strains through the fecal-oral route.

We report the median cDNA viral load of norovirus genogroup II is >100-fold higher than that of genogroup I in the fecal specimens of patients with norovirus-associated gastroenteritis. We speculate that increased cDNA viral load accounts for the higher transmissibility of genogroup II strains through the fecal-oral route.
N orovirus (NoV), a member of the family Caliciviridae in the genus Norovirus, is a major causative agent of viral gastroenteritis, affecting all age groups worldwide (1). NoVs are clustered into 5 genogroups; genogroup I (GI), GII, and GIV infect humans (2). Molecular epidemiologic studies in different countries and regions show that NoV GII is the predominant genogroup circulating in the community; it accounts for most sporadic, nosocomial, and outbreak cases (3). However, its predominance cannot be entirely explained. In this study, we show for the first time that the median cDNA viral load of NoV GII is >100fold higher than that of GI in fecal specimens of patients with NoV-associated gastroenteritis. This finding suggests possible higher transmissibility of GII strains through the fecal-oral route.

The Study
From December 2004 through November 2005, a total of 651 fecal specimens were collected within 48 hours of symptom onset from 627 patients (43.5% male, <1-97 years of age, 26.9% <16 years of age) with symptoms of gastroenteritis at Prince of Wales Hospital, Hong Kong Special Administrative Region, People's Republic of China. All cases were sporadic (defined as having no known related cases). Fecal specimens were stored at −70°C after collection and were processed in batches monthly. Local monthly mean air temperature during the study period was obtained from the Hong Kong Observatory (available from http://www.hko.gov.hk/wxinfo/pastwx/ywx.htm). Viral RNA was purified from fecal specimens and transcribed to cDNA as described (4). All specimens had a detectable level of human β-actin cDNA, which suggests high RNA integrity. Filter tips were used throughout the study to minimize cross-contamination. NoV GI and GII were detected by a quantitative and genogroup-specific real-time PCR assay, as previously described (5). Sterile water was used in place of cDNA as negative control. Three amplicons from each genogroup were directly sequenced to confirm their identities and genogroups on a 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). cDNA viral load was quantified in triplicate per run against 10-fold serial dilutions (10 8 -10 1 copies) of external plasmid standards prepared by cloning genogroup-specific amplicons into vector pCR2.1-TOPO (Invitrogen Corp., Carlsbad, CA, USA). The lower detection limit of the assay was equivalent to 2 × 10 4 copies of cDNA per gram of fecal specimen. Coefficients of variation within and between runs were calculated as the percentage of the ratio between the standard deviation and mean of threshold cycle numbers from the standard curves. The respective intra-and interassay coefficients of variation for NoV GI were 0%-4.1% and 1.9%-5.8%, respectively, and 0.1%-6.1% and 2.7%-6.6%, respectively, for NoV GII. These findings indicate the high reproducibility in viral load quantitation by the assay. Two common gastroenteritis-associated viruses, sapovirus and group A rotavirus, were detected in parallel, as previously described (4,6).
Phylogenetic analysis of NoV isolates was performed by using primer sets G1FF/G1SKR and G2FB/G2SKR for GI and GII, respectively, as described elsewhere (7). Isolates were clustered with the nomenclature system of Zheng et al. (2). Since G1FF/G1SKR and G2FB/G2SKR completely spanned the region amplified by the RT-PCR assay, the 2 primer sets were also used to check for sequence complementarity among target, primers, and probe used in quantitation. Statistical analyses were performed by SPSS version 11.5.1 (SPSS Inc., Chicago, IL, USA), and figures were constructed by Prism version 4.03 (GraphPad Software, Inc., San Diego, CA, USA) and SPSS.
The median cDNA viral load of NoV GI and GII detected in the fecal specimens was 8.4×10 5 (range 2.2×10 4 -2.9×10 10 ) and 3.0×10 8 (range 2.5 × 10 4 -7.7×10 10 ) copies per gram of fecal specimen ( Figure 1A), respectively. Although the range was comparable between the genogroups, the median of NoV GII was >100-fold higher than that of GI (p = 0.0022, 2-tailed Mann-Whitney U test). Similar findings were obtained when NoV GI/GII coinfections (p = 0.0066, Figure 1B) or all viral coinfections (p = 0.0042, Figure 1C) were excluded. Seven of 9 specimens with NoV GI/GII coinfections had higher cDNA viral load of GII than GI, with fold changes from 4 to 452 (median 248) ( Figure 2). Furthermore, while NoV was detected year-round, a marked seasonal trend was evident: higher prevalence occurred in winter months, when the cDNA viral load of GII was generally higher compared with GI (online Appendix Figure 1, available from http://www.cdc.gov/ncidod/EID/vol12no08/06-0081-appG1.htm). Multivariate linear regression model was used to determine the potential association between cDNA viral load, NoV genogroup, and patient's age. After age stratification, the cDNA viral load in fecal specimen was still significantly associated with NoV genogroup (β = 0.390, p = 0.002). However, no significant association was found between cDNA viral load and age of patients (β = −0.060, p = 0.626).
To rule out the possibility of a quantitation artifact due to different stability between genogroups upon storage or freeze-thaw cycle, viral RNA was re-extracted and requantitated from a fecal specimen that had been stored for >6 months and coinfected with both NoV GI and GII. Repeat testing showed no drop in cDNA viral load for either genogroup, which suggests a comparable stability upon storage. Sequence complementarity among target, primers, and probe used in quantitation was also verified. While no sequence mismatch in primers and probe was found among the 7 NoV GI isolates, 5 of the 36 GII isolates had a single mismatch. Thus, the low cDNA viral load of NoV GI measured was unlikely due to sequence mismatching.

Conclusions
In this study, we show for the first time that the median cDNA viral load of NoV GII is >100-fold higher than that of GI in the fecal specimens of patients with NoV-associated gastroenteritis. Neither the possibility of quantitation artifacts as a result of primers and probe mismatching nor stability differences between genogroups on storage was likely to account for our observation. Moreover, 7 of 9 specimens with NoV GI/GII coinfection exhibited higher cDNA viral load of GII than that of GI. Also, the cDNA viral load of NoV GII was usually higher than that of GI for each collection month, a finding that further supports our interpretation. We speculate that the increased cDNA viral load facilitates the transmission of NoV GII from infected persons to susceptible hosts through the fecal-oral route. Studies on other viruses have shown that viral load correlates well with the epidemiology of diseases. For example, the predominance of HIV-1 over HIV-2 has been suggested to be attributed to the higher viral load of HIV-1 (8

Instructions for Infectious Disease Authors Dispatch
Articles should be no more than 1,200 words and need not be divided into sections. If subheadings are used, they should be general, e.g., "The Study" and "Conclusions." Provide a brief abstract (50 words); references (not to exceed 15); figures or illustrations (not to exceed two); and a brief biographical sketch of first author-both authors if only two. Dispatches are updates on infectious disease trends and research. The articles include descriptions of new methods for detecting, characterizing, or subtyping new or reemerging pathogens. Developments in antimicrobial drugs, vaccines, or infectious disease prevention or elimination programs are appropriate. Case reports are also welcome.